R Squared’s BioAtla BCAB Stock Holding History

R Squared’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-234	Closed	-$4.06K	–	476
2025 Q1	$4.06K	Buy	234 +209	+836%	+$4.47K	﹤0.01%	289
2024 Q4	$733	Buy	+25	New	+$2.1K	﹤0.01%	1523

Other funds holding BCAB

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

R Squared's BCAB Position: Q2 2025 in Review

R Squared sold out of BioAtla (BCAB) in Q2 2025, closing a stake of 234 shares — an estimated $4.06K sold.

R Squared first reported a position in BCAB in Q4 2024 and held it in 2 quarters. The position peaked at $4.06K in Q1 2025. 39 funds tracked by Wall St. Rank hold BCAB as of Q2 2025.

R Squared reported no remaining BioAtla position as of Q2 2025 after selling out during the quarter.
R Squared sold 234 BioAtla shares in Q2 2025, an estimated $4.06K.
R Squared first reported a position in BioAtla in Q4 2024 and held it in 2 quarters.
R Squared's BioAtla position peaked at $4.06K in Q1 2025.
39 funds tracked by Wall St. Rank held BioAtla as of Q2 2025.

Based on R Squared's 13F filing for Q2 2025, filed 31 Jul 2025.